Clinical acceptance of a molecular imaging agent: a long march with [99mTc]TRODAT

Nucl Med Biol. 2007 Oct;34(7):787-9. doi: 10.1016/j.nucmedbio.2007.03.010. Epub 2007 May 11.


In the past 10 years, significant progress has been made in using a technetium-99m dopamine transporter imaging agent, [99mTc]TRODAT, for routine clinical studies. Developing a molecular imaging agent from bench to the bedside is more than a simple scientific venture. Currently, Taiwan is the only place where [99mTc]TRODAT is approved for routine clinical use in the diagnosis of Parkinson's disease. The trials and tribulations of developing [99mTc]TRODAT for routine clinical use in Taiwan provide an interesting case study in how to (critics may say, how not to) develop a molecular imaging agent.

Publication types

  • Review

MeSH terms

  • Brain / diagnostic imaging*
  • Humans
  • Molecular Probe Techniques / trends*
  • Organotechnetium Compounds*
  • Parkinson Disease / diagnostic imaging*
  • Practice Patterns, Physicians' / trends*
  • Radionuclide Imaging
  • Radiopharmaceuticals
  • Taiwan
  • Tropanes*


  • Organotechnetium Compounds
  • Radiopharmaceuticals
  • Tropanes
  • technetium Tc 99m TRODAT-1